+111.7%
RIOT vs MRNA
+34.8%
+76.9%
-66.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.5% | +5.4% | -2.9% | +2.0% |
| 7D | -1.5% | -1.1% | -0.4% | -1.4% |
| 30D | +5.7% | +126.1% | -120.5% | -10.1% |
| 3M | -17.9% | +190.0% | -207.9% | -36.3% |
| 6M | +45.0% | +157.2% | -112.3% | +16.3% |
| YTD | +69.5% | +388.2% | -318.7% | +13.4% |
| 1Y | +37.2% | +467.0% | -429.8% | -12.5% |
| 3Y | +111.7% | +36.1% | +75.7% | +82.5% |
| All | +111.7% | +34.8% | +76.9% | +82.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling